CRISPR-Cas9 genome editing was used to induce GATA1s in HSPCs of fetal, neonatal, and adult origin, leading to distinct ontogeny-specific disturbances in megakaryopoiesis and erythropoiesis.
The tumor suppressor miR-193b is downregulated in AML. Expression induces leukemic cell death through repression of MAPK signalling, making miR-193b a candidate for RNA-based therapy.
Introducing CRISPRater: a tool for more efficiently selecting effective sgRNAs in CRISPR-Cas9 applications. In addition, we provide a meta-analysis and individual evaluation of five current prediction algorithms.
Jan-Henning Klusmann will become full professor and department head of Pediatric Hematology/Oncology at the Universitätsklinikum Halle! He will begin there in January, and students will follow in March.
PD Dr. Jan-Henning Klusmann is a co-winner of the this year's Robert J. Arceci Award, a unique prize that offers resources and freedom to pioneers and innovators in childhood cancer research.
Our latest publication provides a non-coding RNA expression atlas across normal and malignant blood cells. We highlight the biological and clinical importance of ncRNAs, and the need for further study.
Two publications in one day: 1) Leveraging CRISPR-Cas9 to model translocation-driven leukemia yields new insight into the importance of environmental cues during disease induction.
Two publications in one day: 2) Targeted gene correction in induced pluripotent stem cells from Kostmann disease patients reverted the disease phenotype and rescued granulocytic function.
We are looking for a proactive and creative team player capable of designing and carrying out experiments independently. Experience with cell culture and molecular biology preferred.
Results from the international ML-DS 2006 trial indicate that children with Down syndrome acute myeloid leukemia can be cured with a less intensive, less cytotoxic treatment regime.